Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single Center, Phase 1/2 Study to Evaluate the Safety and Efficacy of DANAGALEX (scAAV9/AGA) in Participants With Aspartylglucosaminuria (AGU)

NCT07530796 is registered in ClinicalTrials.gov with Rare Trait Hope as lead sponsor.

NCT NCT07530796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single Center, Phase 1/2 Study to Evaluate the Safety and Efficacy of DANAGALEX (scAAV9/AGA) in Participants With Aspartylglucosaminuria (AGU)
Lead sponsor
Rare Trait Hope
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
May 1, 2032
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aspartylglucosamidase (aga) deficiency, aspartylglucosaminuria